organ prolapse and preterm premature rupture of membranes, the 2 conditions which have in common weakening of the tensile strength of tissues, are thought to be caused, in part, by abnormal extracellular matrix synthesis and/or catabolism. We identified a new single nucleotide polymorphism (NT_010194( LOXL1):g.45008784A>C) in the promoter of the LOXL1 gene, which is essential for elastin synthesis. Promoter studies showed that the minor ''C'' allele had significantly greater activity than the major ''A'' allele. Case-control studies examined the association of the alleles of this single nucleotide polymorphism with pelvic organ prolapse and preterm premature rupture of membranes. When comparing allele frequencies and genotypes in pelvic organ prolapse cases versus controls, no significant associations were found. A case-control study conducted in African American neonates also found no significant associations between the promoter alleles and preterm premature rupture of membranes. We conclude that a functional single nucleotide polymorphism exists in the promoter region of the LOXL1 gene. Association studies suggest that the promoter single nucleotide polymorphism does not contribute significantly to risk of pelvic organ prolapse or preterm premature rupture of membranes.
INTRODUCTION
Pelvic organ prolapse (POP) and preterm premature rupture of membranes (PPROM) are the two conditions that are thought to be caused, in part, by abnormal extracellular matrix synthesis and/or catabolism. Because the prevalence of POP increases with age, the changing demographics of the world's population will result in a growing number of affected women. Although pelvic floor disorders are not life-threatening medical conditions, they can have a significant negative impact on quality of life. 1, 2 The pathophysiology of POP is multifactorial with risk factors that may be categorized as predisposing, inciting, promoting, or decompensating. [3] [4] [5] [6] [7] [8] [9] Depending on the combination of these risk factors in an individual, prolapse may or may not develop over her lifetime. At present, the potential impact of genetic factors has not been clearly elucidated. Multiple studies have identified parturition and advanced age to be risk factors associated with development of pelvic floor disorders, but identification of positive family history and familial clustering provides evidence that a genetic component exists. 9, 10 Observations of lower rates of prolapse in African American women have also raised the question of genetic susceptibility/protection, with inherited abnormalities in collagen biosynthesis a potential target for research. 11 Genetic variants that potentially confer risk of POP have only recently been reported in the LAMC1, COL3A1, and estrogen receptor a and b genes. [12] [13] [14] [15] Abnormalities in extracellular matrix metabolism and repair present a possible genetic explanation for the development of POP. Female pelvic tissues are rich in elastic fibers that turn over slowly in most adult tissues but undergo massive remodeling in the reproductive organs through pregnancy and birth. In the generation of a LOXl1-deficient mouse model, approximately one third of the female mutant mice developed severe POP after the first litter, and all the remaining two thirds developed prolapse after the second litter highlighting the essential role for elastic fiber homeostasis in pelvic floor remodeling postpartum. 16, 17 A recent study of women with stage III or greater prolapse showed suppression of the lysyl oxidase-like 1 (LOXL-1) protein in uterosacral ligaments. 17 The gene encoding this enzyme represents a potential locus where genetic variation may predispose women to the development of POP. This target gene has not been previously investigated in the setting of human POP.
Fetal membrane rupture, occurring before 37 weeks of completed gestation, is referred to as PPROM. Preterm premature rupture of membranes complicates 1% to 4% of all pregnancies and is the leading identifiable cause of preterm birth, which is the major cause of neonatal mortality and morbidity. 18 Preterm premature rupture of membranes and preterm birth are more common in African Americans.
The tensile strength of the fetal membranes, which are composed of the amnion and chorion, is provided predominantly by the extracellular matrix of the amnion. 18, 19, 20 Fetal membranes that rupture prematurely have reduced collagen content, which could be the result of diminished synthesis or increased catabolism. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Reduced extracellular matrix production is related to risk of PPROM. 29, 30 Fetuses affected with some forms of Ehlers-Danlos syndrome and other connective tissue disorders are more likely to be born prematurely as a result of PPROM. 18 Moreover, a fetal polymorphism in the SER-PINH1 gene, which encodes heat-shock protein 47 (Hsp47), an intracellular chaperone for collagen proteins which governs collagen elaboration, is associated with risk of PPROM in African Americans. 30 Lysyl oxidases are copper-dependent amine oxidases that are key enzymes involved in collagen and elastin synthesis and repair. Lysyl oxidases are responsible for the formation of cross-linking between the collagen and elastin fibrils, without which these proteins are prone to degradation leading to weakened connective tissues. Distinct from the prototypic lysyl oxidase (LOX), the LOXL1 protein localizes specifically to sites of elastogenesis and is an essential enzyme in producing the scaffold that ensures the spatially defined deposition of elastin. 16, 31 The goals of this study were to: (1) determine whether functional single nucleotide polymorphisms (SNPs) exist in the promoter region of the LOXL1 gene; (2) determine whether women with and without POP demonstrate a significant difference in the carriage of the SNP alleles; and (3) determine whether the SNP alleles are associated with risk of PPROM.
MATERIALS AND METHODS

Identification of SNPs
To search for SNPs in the LOXL1 promoter region, an 1120 base pair (bp) sequence was amplified from 10 DNA samples of unknown ethnicity, and this DNA was then directly sequenced. To amplify the LOXL1 promoter region, AmpliTaq Gold with Gene Amplification from Applied BioSystems, manufactured by Roche in Branchburg, New Jersey, was used. Polymerase chain reaction (PCR) primers used in the amplification of the LOXL1 gene were forward: 5 0 -AGAGCAGTATTTG-GAGTGTG-3 0 and reverse: 5 0 -CCCACTCTGAAT-GAATAAGC-3 0 . The conditions for amplification of LOXL1 were initialization at 94 C for 3 minutes, denaturation was begun at 94 C for 30 seconds, annealing at 57 C for 45 seconds, extension/elongation at 72 C for 45 seconds for a total of 35 cycles, followed by elongation at 72 C for 7 minutes. We then acquired DNA samples from 10 Western Europeans from the Centre d'Etude du Polymorphisme Humain (CEPH) DNA collection for analysis under the same conditions stated above.
Construction of Promoter-Reporter Plasmids
To determine whether the À659 A>C SNP in the LOXL1 promoter region influences transcription of the LOXL1 gene, we cloned the 1120 bp fragment of the LOXL1 promoter into the pGL3 vector, which contains the firefly luciferase gene as a reporter. The promoter fragment extended from À1431 bp to À310 bp from the ATG codon. Based on cDNA sequences deposited in GenBank (Accession Numbers: NM005576 and BC068542), the promoter construct extends into the transcribed region of the LOXL1 gene by at least 17 bp. A mutagenesis kit was used to create the targeted alleles with a uniform backbone sequence (Stratagene, QuikChange Site-Directed Mutagenesis Kit, La Jolla, CA). The DNA sequences of the promoter constructs were confirmed before use, and 3 different plasmid preparations were prepared for each construct.
Cell Culture and Transfection
Human dermal fibroblasts were cultured in Dulbecco's Modified Eagle's Medium (DMEM). The media was supplemented with 10% fetal bovine serum and antibiotics (100 U/mL penicillin G, 100 U/mL streptomycin sulfate). Cells were maintained at 37 C in a water saturated atmosphere under 5% CO 2 in air. For transfection, dermal fibroblasts were grown in a 12-well culture plate. Cells were transfected using FuGene 6 transfection reagent (Roche Diagnostics, Indianapolis, IN) with 6 mg of the pGL3 vector containing the LOXL1 promoter fragments. In each transfection well, 25 ng of pRL-TK (Promega, Madison, WI), a control plasmid expressing Renilla reniformis luciferase, was used to correct for transfection efficiency. The transfected cells were cultured for 48 hours in medium before collecting the cells for the luciferase assays.
Luciferase Assays
After 48 hours of culture, the transfected cells were lysed in lysis buffer, and 20 mL aliquots of supernatant were assayed for luciferase activity using the Dual-Luciferase Reporter Assay system (Promega). Promoter activities were expressed as the ratio between Photinus luciferase and R reniformis luciferase activities.
Study Populations
After obtaining institutional review board approval, a control population of women with < stage II POP according to the Pelvic-Organ-Prolapse Quantification System (POP-Q) was prospectively recruited from the Urogynecology and benign gynecology clinics of a study author (CAM). Control participants were recruited to match cases on the basis of age, self-reported race, menopausal status, smoking history, body mass index (BMI), and parity. Exclusion criteria for all study participants included a personal history of a systemic collagen disorder such as Ehlers-Danlos or Marfan's syndrome. Cases were defined as women with ! stage II POP and were collected via 2 different methods in Caucasian women in an attempt to expedite study completion. Prospective recruitment of Caucasian and African American women with ! stage II POP who presented to the Urogynecology clinic at VCU Medical Center was conducted in the same manner in which control women were enrolled. In addition, Caucasian cases were retrospectively collected by accessing tissue samples of women who underwent reconstructive surgery for ! stage II POP between January 2004 and January 2006 at the VCU Medical Center. Demographic data for these women were extracted from the Urogynecology case log that is maintained by the division at VCU Medical Center. Informed consent was obtained for all participants who were prospectively enrolled. For this group, demographic data were obtained at the time of consent, including age, race, parity, menopausal status, smoking status, and BMI. Samples for genomic DNA isolation were collected by buccal smears using Simhelix Buccal Swabs, the extraction of which was performed using Simhelix Buccal Swab DNA Isolation Kit from Boca Scientific, Boca Raton, FL.
Participants in the PPROM case-control study were self-reported African American women, and their neonates receiving obstetrical care at the Hospital of the University of Pennsylvania or Hutzel Hospital. Written informed consent was obtained from mothers before collection of the samples. This study was approved by the respective institutional review boards. Control samples (N ¼ 142) were obtained from neonates of singleton pregnancies delivered at term of mothers with no prior history of PPROM or preterm labor. Case samples (N ¼ 249) were collected from neonates from pregnancies complicated by rupture of membranes before 37 weeks of gestation. The diagnosis of membrane rupture was based on pooling of amniotic fluid in the vagina, amniotic fluid ferning patterns, and a positive nitrazine test. Women with multiple gestations, fetal anomalies, trauma, connective tissue diseases, and medical complications of pregnancy requiring induction of labor were excluded.
Because the African Americans are not the isolated populations, there is a chance that any observed association could be a result of admixture stratification. To evaluate the possible effects of population stratification, we evaluated 29 ancestry-informative markers to calculate the individual biogeographical ancestry levels of the persons in the study in the context of the 2 primary parental populations (West African and Western European) as previously reported. 30 This assessment of the population structure showed no significant difference in the genetic profiles between PPROM cases and the controls (P > .05).
Genotyping
Polymerase chain reaction was performed on the samples using AmpliTaq Gold with Gene Amplification from Applied BioSystems, manufactured by Roche in Branchburg. Polymerase chain reaction primers used in the amplification of the LOXL1 gene include forward: 5 0 -GAACATGCAAAGAGGGTGTGTC-3 0 and reverse: 5 0 -CAGACCTGCCTCTGAGGAAGG-3 0 . The conditions for amplification of LOXL1 were initialization at 94 C for 3 minutes, denaturation at 94 C for 30 seconds, annealing at 57 C for 45 seconds, extension/elongation at 72 C for 45 seconds for a total of 35 cycles, followed by elongation at 72 C for 7 minutes. Allele discrimination was performed on PCR products from cases and controls using the 5 0 nuclease assay, Applied Biosystems TaqMan SNP Genotyping Assay. Conditions for this reaction were initialization at 50 C for 2 minutes, 95 C for 10 minutes, denaturation at 95 C for 15 seconds, and annealing/extension at 60 C for 1 minute for a total of 40 cycles.
Electrophoretic Mobility Shift Assays
Nuclear proteins were extracted using Novagen NucBuster Protein Extraction Kit (EMD Biosciences, Darmstadt, Germany). Double-stranded oligonucleotide probes were constructed: À659 A sense: 5 0 -CATTCCAGCC-CAAACGAGAAGCCAG-3 0 ; À659 A antisense: 5 0 -CTGGCTTCTCGTTTGGGCTGGAATG-3 0 ; À659 C sense: 5 0 -CATTCCAGCCCACACGAGAAGCCAG-3 0 ; À659 C antisense: 5 0 -CTGGCTTCTCGTGTGGGC-TGGAATG-3 0 . The double-stranded oligonucleotides were labeled with T4 polynucleotide kinase and [g 32 P]adenosine triphosphate (ATP). The electrophoretic mobility shift assay (EMSA) binding reaction was mixed in 4Â EMSA buffer (Novagen) with 10 mg of nuclear protein, 1 Â 10 5 counts per minute (cpm) of 32 P-labeled double-stranded oligonucleotide probe (1 ng) with or without unlabeled competitor probe in a total volume of 10 mL. The reaction incubated at room temperature for 30 minutes and then was subjected to 8% polyacrylamide gel electrophoresis (PAGE) at 250 V for 3 hours. The dried gels were next exposed to x-ray film.
Analysis of LOXL-1 Messenger RNA in Cultured Dermal Fibroblasts
We obtained 5 dermal fibroblasts lines from the American Type Culture Collection (Rockville, MD) and genotyped them for the LOXL1 promoter SNP. We identified 3 cell lines homozygous for the major ''A'' allele and 2 that were heterozygous for the SNP. Cells were cultured as described by Wang et al and RNA was extracted for quantitative real-time PCR assay of the LOXL-1 message as described using a forward primer sequence of 5 0 -AGAGCAGTATTTGGAGTGTG-3 0 and a reverse primer sequence of 5 0 -CCCACTCTGAATGAA-TAAGC-3 0 and SYBR green. The LOXL-1 messenger RNA (mRNA) abundance was normalized to actin mRNA. 17, 30, 32 
Statistical Analysis
Student t test and Fisher exact test were used to assess significant differences in demographic characteristics between participants in the case-control groups. Significant differences in activities among the different promoter constructs were evaluated using analysis of variance (ANOVA) and Duncan's multiple range test with P < .05 considered significant. The chi-square tests, odds ratios, and 95% confidence intervals (CIs) were used to determine the significance of association between LOXL1 genotypes and POP.
RESULTS
A New SNP in the Promoter Region of the LOXL1 Gene
In searching for a polymorphism that could affect the production of lysyl oxidase like-1 protein, we identified a new single nucleotide polymorphism in the promoter region of LOXL1 gene (NT_010194(LOXL1):g. 45008784A>C), lying at À659 from the ATG codon, that has not previously been described. The TFSEARCH (http://www.cbrc.jp/research/db/TFSEAR) and ConSite (http:/www.phylofoot.org/consite) programs, which identify putative response elements, did not reveal a known response element around the (NT_010194 (LOXL1):g.45008784A>C) SNP.
Distribution of the LOXL1 À659 A/C Promoter SNP Across Populations
We analyzed the allele frequencies of the À659 A>C SNP in DNA samples from various populations (Table 1) . We found that the À659 ''A'' allele was present in the highest frequencies among all populations studied. The minor ''C'' allele frequency was found to be highest in the Caucasian, North African, and African American population.
Functional Significance of the À659 A > C LOXL1 Promoter SNP
To determine whether the (NT_010194(LOXL1):g. 45008784A>C) SNP was functional, we performed promoter studies in the context of dermal fibroblasts. In these studies, the minor ''C'' allele displayed significantly greater (1.5-to 2.3-fold greater, P < .001) promoter function in dermal fibroblasts as compared with the major ''A'' allele ( Figure 1 ). From these data, we can speculate that the ''C'' allele is associated with increased production of LOXL-1 protein compared with the ''A'' allele, which might result in greater elastin production and increased tensile strength of tissues.
We measured LOXL-1 mRNA in cultured dermal fibroblasts and found that the mean abundance of these transcripts relative to actin mRNA was 1.37-fold higher in cells heterozygous for the SNP compared with cells homozygous for the major ''A'' allele: (A/A genotype: 0.86 + 0.09 [X + SE, N ¼ 3]; A/C genotype: 1.18 [range 1.08-1.28, N ¼ 2]), consistent with enhanced LOXL1 gene transcription in the presence of the À659 ''C'' allele.
Proteins in nuclear extracts from dermal fibroblasts bound specifically to labeled double-stranded oligonucleotide probes containing the LOXL1 promoter SNP sequences (Figure 2 ). However, there did not appear to be a significant difference in the affinity for binding to the 2 different SNP allele sequences based on competition studies with the double-stranded oligonucleotides representing the 2 promoter alleles.
Case-control Study of POP and the À659 LOXL1 Promoter SNP
In a study to test the association of the (NT_010194 (LOXL1):g.45008784A>C) SNP with POP, we genotyped a total of 278 women in a case-control study design, recognizing that ''controls'' could potentially develop POP later in life. The demographic characteristics of the cases (n ¼ 137) and controls (n ¼ 141) are presented in Table 2 . In all, 212 women were Caucasian, and 66 were African American. No significant differences existed in age, parity, BMI, smoking, or menopausal status. The distribution of cases by stage of prolapse was 25% stage II, 65% stage III, and 10% stage IV.
The genotypes for the À659 SNP in the LOXL1 promoter were analyzed in POP cases and controls. Genotyping was successful in 137 controls and 130 cases. The major ''A'' allele had a frequency of 0.58 in controls and 0.65 in cases. Although there was a trend for the frequency of the ''A'' allele, which has lower promoter activity than the minor ''C'' allele, to be present at lower frequency in the controls, this was not a statistically significant difference (P ¼ .68 odds ratio ¼ 1.32; 95% CI: 0.92, 1.91). Comparing genotypes, carriage of the minor ''C'' allele (ie, comparing ''A/A'' individuals with ''A/C'' and ''C/C'' genotypes) revealed no association with POP (odds ratio ¼ 1.15; 95% CI: 0.56, 2.34). A sub-analysis of allele frequencies by racial/ethnic group also revealed no significant associations for Caucasians (controls ¼ 106; cases ¼ 97; P ¼ .28 odds ratio ¼ 1.24 [95% CI: 0.824, 1.88]) or African Americans (controls ¼ 31, cases ¼ 33; P ¼ .27 odds ratio ¼ 1.68 [95% CI: 0.60, 4.85]). Nor did an analysis comparing controls with cases having POP > stage III, when stage II participants were not considered (odds ratio ¼ 1.45; 95% CI: 0.58, 3.51) or when stage II POP participants were added to the control, did the association reach borderline significance. (P = .047 odds ratio ¼ 1.46; 95% CI: 0.98, 2.19).
A Case-control Study of PPROM in African American Neonates
To determine whether the À659 LOXL1 promoter polymorphism is associated with the risk of PPROM, we performed a case-control study in African Americans, focusing on the genotype of the offspring based on the assumption that the genotype of the extraembryonic tissues (fetal membranes) represents the primary determinant of risk of PPROM.
Analysis of the demographic characteristics of the control population, neonates born at term from normal pregnancies, and the cases, neonates from pregnancies complicated by PPROM revealed no significant differences in maternal age, gravidity, and parity as previously described. 30 However, the length of gestation (controls: 39.3 + 1.2 [SD] weeks; cases: 31.8 + 2.9, P < .0001) and birth weight (controls: 3308 + 485 g; cases: 1934 + 500, P < .0001) were significantly lower in the PPROM group, as expected. There was no significant association between the À659 LOXL1 promoter SNP alleles and PPROM based on allele frequencies (Minor ''C'' allele frequency in 142 controls: 0.29; Minor ''C'' allele frequency in 249 cases: 0.306; P ¼ .66, odds ratio ¼ 1.08, [95% CI: 0.77, 1.49]). Moreover, there was no significant difference when PPROM and control neonates were compared by genotype (A/A vs. A/C or C/C; P ¼ .28).
Because the urban African American population in the United States from which our participants were drawn is heterogeneous, we previously performed analyses using 29 ancestry informative markers to determine whether population stratification could have affected our findings. There was no significant difference in ancestry among cases and controls analyzed in this study using a dihybrid model. 30, 32 
DISCUSSION
We have described a new LOXL1 promoter SNP that is functional in plasmid reporter assays and associated with differences in LOXL-1 mRNA abundance. The SNP is embedded in a DNA sequence, which is not identified in public databases as a known transcription binding motif, but the DNA sequence surrounding the SNP is specifically recognized by fibroblast nuclear proteins, consistent with a functional role for this element. The nature of the protein binding to the SNP element remains to be determined. The minor ''C'' allele that had greater promoter activity might be expected to increase elastin production and therefore protects against both POP and PPROM. Because there were no significant differences in the frequency of the ''C'' allele between Caucasians and African Americans, a priori it is unlikely that this LOXL1 promoter SNP contributes to the differences in incidence of POP and PPROM among these 2 ethnic/racial groups.
Although the in vitro studies indicate that the SNP is functional, it was not found to have a major influence on risk of POP or PPROM in case-control studies. The limited impact may be explained by the relatively modest influence on promoter activity, which is consistent with the inability to detect qualitative differences in the affinity of fibroblast nuclear extract protein binding to the oligonucleotide sequence representing the 2 alleles. However, we cannot rule out the possibility that larger sample sizes would have revealed small but statistically significant associations especially if the case study group is restricted to POP > Stage 2 and Stage (less than/equal to) are considered as controls. A sample size calculation indicated that with the number of total cases and controls in our study, it would be possible to detect relative risk of POP of 2.5-fold with 80% power and a 2-sided a of .05. Our findings do not exclude the possibility that other LOXL1 variants contribute to risk of POP or PPROM. Indeed, a number of SNPs have been identified in the LOXL1 locus including introns, and 9 SNPs in the coding sequence archived in the NCBI SNP public database. Divisional Intramural Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development. GF was the recipient of an SGI fellowship for medical students. Four of the latter SNPs result in missense amino acid substitutions (rs1048661; rs3825942; rs28706550; rs35203737). 33 The contributions of these variants to POP and PPROM remains to be evaluated. Moreover, other mechanisms influencing LOXL-1 expression, including epigenetic control and posttranscriptional and posttranslational processes, could play roles in determining elastin content and therefore risk of POP and PPROM.
Polymorphisms in the LOXL1 gene are not only of interest relative to POP and PPROM but to glaucoma as well. Common sequence variants have been identified in the LOXL1 gene that appears to confer susceptibility to development of exfoliative glaucoma. Two of the LOXL1 coding sequence SNPs noted above (rs048661 and rs3825942) have been found to be associated with exfoliation syndrome and exfoliation glaucoma in different populations. 34, 35 Whether the LOXL1 promoter polymorphism described here has an impact on the risk of developing exfoliation syndrome with and without glaucoma remains to be determined. The 2 coding SNPs mentioned above that are strongly associated with exfoliation syndrome and exfoliation glaucoma show strong linkage disequilibrium and are thought to contribute to the disease phenotype as a result of abnormal protein-protein interactions, which results in the accumulation of extracellular matrix material (elastosis). 34, 35 Whether this pathophysiological mechanism, which affects ocular tissues, could contribute to risk of POP and PPROM is not known because they have not been evaluated for a role in these conditions, and there is no published evidence that we are aware of linking POP or PPROM with exfoliation syndrome and/or exfoliation glaucoma. Moreover, the LOXl1-deficient mice are not specifically reported to phenocopy human exfoliation syndrome. 36 However, if such association exists between exfoliation syndrome and/or exfoliation glaucoma and POP and/or PPROM, it would heighten interest in the LOXL1 gene risk locus for these conditions.
In conclusion, we have identified a new SNP in the promoter region of the LOXL1 gene that has functional significance as determined by promoter activity and examined its relationship to 2 disorders thought to be associated with altered matrix metabolism, POP and PPROM. This is the first time, to our knowledge, that a variant in the LOXL1 gene has been investigated in the setting of these conditions. There was no significant association between the SNP alleles and a diagnosis of POP. There was also no evidence for an association of the LOXL1 promoter SNP in the fetus and PPROM. Collectively, these observations suggest that the À659 LOXL1 promoter polymorphism is not a significant contributor to the 2 women's health problems studied.
